Chemical inhibitors of A930016P21Rik can be diverse in their mechanisms of action, each targeting different aspects of cellular signaling pathways to achieve inhibition of this protein's function. Staurosporine, for instance, is an effective kinase inhibitor that binds to the ATP-binding site of kinases, thus preventing ATP from binding and phosphorylating substrates. Since A930016P21Rik is a kinase, Staurosporine directly inhibits its activity by blocking this essential function. Similarly, GW5074 targets Raf kinases, which are part of many signaling cascades that can regulate proteins like A930016P21Rik. By inhibiting Raf, GW5074 indirectly prevents the activation of A930016P21Rik. LY294002 selectively inhibits PI3K, an upstream component of the PI3K/Akt pathway, which is crucial for many cellular processes. This inhibitor prevents the activation of Akt, which in turn can regulate proteins like A930016P21Rik, leading to its inhibition. PD98059 and U0126 both specifically inhibit MEK1/2, thereby blocking the activation of ERK and inhibiting signaling pathways that would otherwise lead to the activation of A930016P21Rik.
Furthermore, SP600125 and SB203580 target the JNK and p38 MAPK pathways, respectively, both of which are implicated in stress responses and inflammation. By inhibiting these kinases, the chemicals prevent the downstream signaling that may be required for the proper function of A930016P21Rik. PP2 and Dasatinib are known to inhibit Src family kinases and, in the case of Dasatinib, Bcr-Abl as well. Src kinases are involved in numerous signaling pathways, and their inhibition by these chemicals results in the suppression of pathways that can lead to the functional activation of A930016P21Rik. Rapamycin specifically inhibits mTOR, a central regulator of cell growth and metabolism, and by doing so, it can halt processes that involve A930016P21Rik. Lastly, Bortezomib and MG132 are proteasome inhibitors that alter the degradation of regulatory proteins. By inhibiting the proteasome, these chemicals can stabilize proteins that control the cell cycle, leading to an indirect inhibition of A930016P21Rik by influencing the protein stability and regulatory proteins associated with A930016P21Rik's functional state. Each of these chemicals targets specific molecular interactions and pathways that are essential for A930016P21Rik's activity, providing multiple avenues of inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
An alkaloid that inhibits protein kinases. Given that A930016P21Rik is a kinase, staurosporine can directly inhibit its kinase activity by competing for the ATP-binding site. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
A selective inhibitor of Raf kinases. Since A930016P21Rik is part of signaling cascades involving Raf, GW5074 can inhibit the protein by preventing Raf-mediated activation processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, which can inhibit the PI3K/Akt pathway where A930016P21Rik may be involved. By inhibiting upstream PI3K, LY294002 prevents Akt phosphorylation and subsequent activation of A930016P21Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK, which works upstream in the MAPK/ERK pathway. A930016P21Rik, being regulated by this pathway, can be inhibited by PD98059 through the prevention of ERK activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is involved in stress and cytokine signaling. A930016P21Rik activity can be inhibited by SP600125 by blocking JNK-mediated signaling processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor, which can inhibit the p38 MAPK pathway. Since A930016P21Rik is potentially regulated by this pathway, SB203580 can inhibit its activity by blocking p38 signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
A Src family kinase inhibitor. By inhibiting Src kinases, PP2 can inhibit signaling pathways that A930016P21Rik is involved in, leading to its functional inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A multi-targeted inhibitor, known to inhibit Src family kinases and Bcr-Abl. A930016P21Rik, through its involvement in Src-related pathways, can be inhibited by Dasatinib. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, which can inhibit the mTOR pathway. A930016P21Rik can be functionally inhibited by Rapamycin through the blockade of mTOR signaling, affecting pathways in which A930016P21Rik is involved. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Inhibitor of MEK1/2, thereby inhibiting ERK activation. A930016P21Rik, which may be regulated by the ERK pathway, can be inhibited by U0126 through the disruption of MEK/ERK signaling. | ||||||